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Abstract
Functional neuroimaging for the dopamine transporter (DAT) is used to distinguish drug-
induced parkinsonism (DIP) from subclinical Parkinson’s disease (PD). Although DIP
patients who show a normal DAT image are expected to recover completely, some do not.
We investigated whether these patients showed changes in striatal DAT activity using semi-
quantitative analysis of 18F-FP-CIT PET data. DIP patients with visually normal DAT images
were selected from medical records. The subjects were classified as patients who recov-
ered partially (PR) or completely within 12 months (CR). The 18F-FP-CIT uptake in each
striatal subregion was compared between the CR and the PR groups. In total, 41 and 9
patients of the CR and PR groups were assessed, respectively. The two patient groups
were comparable in terms of clinical characteristics including age, sex, and severity of par-
kinsonism. From semi-quantitative analysis of the PET image, the PR patients showed a rel-
atively lower ligand uptake in the ventral striatum, the anterior putamen and the posterior
putamen compared with the CR patients. This result suggests that persistent DIP in patients
with visually normal DAT imaging may be associated with subtle decrement of DAT activity.
Introduction
Drug-induced parkinsonism (DIP) is commonly seen in movement disorder clinics [1, 2].
Although the parkinsonian symptoms develop after administration of certain drugs, there is
heterogeneity in the nigrostriatal status among patients with DIP. Up to 43% of them show
normal activity of nigrostriatal neurons, suggesting that their parkinsonism is caused solely by
the offending drugs (pure DIP) [3–5]. The remainder shows impaired activity of nigrostriatal
neurons, hence their parkinsonism may develop by unmasking the preclinical stage of Parkin-
son's disease (PD) by the offending drugs (unmasked PD). However, the characteristics of par-
kinsonian symptoms are insufficient to distinguish pure DIP from unmasked PD [6]. Another
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report showed that asymmetric parkinsonism is more prevalent in unmasked PD, but a third
of patients with pure DIP also had asymmetry [7]. For this reason, functional imaging tech-
niques to assess the nigrostriatal presynaptic status, especially that using ligands of the dopa-
mine transporter (DAT), are used to distinguish pure DIP from unmasked PD [6–13].
In addition, several early reports showed that patients developed PD after complete remis-
sion of DIP (antedated PD) [14–16]. A recent study reported two patients whose parkinsonism
recurred within 2 years of full remission, and their DAT activities were nearly normal initially
but were decreased at the time of the follow-up scan [13]. In contrast, pathological studies
revealed neuronal loss of substantia nigra and Lewy bodies in the completely recovered patients
with DIP [17, 18]. Taken together, it seems that gap exists between the clinical symptoms and
pathologic or imaging findings.
Interestingly, some DIP patients who have normal DAT activity show persistent parkinson-
ism after the cessation of the offending drug [10, 11, 19]. Although the DAT imaging of these
patients looks normal, the persistent symptoms may imply permanent damage in the dopami-
nergic pathway. Recently, a population-based elderly cohort study showed that the risk of PD
was increased by 3.2-fold after exposure to neuroleptics [20]. This result also implies that DIP
is a risk factor for progressive dopaminergic degeneration.
In this study, we investigated whether there is any change in DAT activity in partially recovered




We reviewed the medical records from a movement disorder clinic of a tertiary referral center,
and selected the DIP patients. DIP was diagnosed according to a previously proposed criteria
as follows [21]: (1) the presence of two or more cardinal symptoms of parkinsonism, (2) an
absence of parkinsonian symptoms before exposure to the offending drug, (3) a disappearance
or significant improvement in parkinsonism after withdrawal of the offending drug, (4) no bet-
ter explanation for the parkinsonism. To rule out patients with unmasked PD or vascular par-
kinsonism, those showing abnormal findings in either brain MRI or 18F-FP-CIT PET scans
were excluded. After semi-quantitative analysis of the DAT density, we excluded the patients
whose DAT density in any subregion was lower than 2 standard deviations (SD) below the
mean of the normal data [12]. The normal DAT density value was obtained from 68 healthy
controls (age 66.5 ± 7.4 years, male/female 25/43) who had been administered 18F-FP-CIT PET
for a medical check-up. The normal DAT data of the controls are shown in Table 1.
The patients were divided according to their degree of recovery. The patients whose parkin-
sonian symptoms did not recover completely within 12 months after discontinuing the offend-
ing drug were classified as the "partial recovery (PR)" group, and those who recovered
Table 1. Normal data of 18F-FP-CIT uptake. Mean value and standard deviation (SD) of each striatal subregions were from 68 healthy controls. Patient
who showed uptake lower than mean-2SD in any subregion was excluded from this study.
Caudate Ventral striatum Whole putamen Anterior putamen Posterior putamen
Mean 2.53 3.12 3.43 3.75 3.23
SD 0.65 0.64 0.69 0.81 0.63
Mean-2SD 1.23 1.84 2.05 2.13 1.97
SD: standard deviation
doi:10.1371/journal.pone.0157410.t001
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completely from DIP were classified as the "complete recovery (CR)" group. The patients with
a follow-up duration shorter than 12 months without full recovery were excluded.
Ethics statement
The study protocol was approved by the institutional review board (IRB) on human experi-
mentation, and was exempt from providing informed consent by the IRB due to the retrospec-
tive design. All information of patients was anonymized prior to the analyses.
Acquisition of 18F-FP-CIT PET data
The 18F-FP-CIT PET scans were performed using a GE PET-CT DSTe scanner (GE Discovery
STE, GE Healthcare Technologies, Milwaukee, WI, USA), which obtains images with a three-
dimensional resolution of 2.3 mm full width at half-maximum. All subjects fasted for at least 6
hours before the PET scan. After fasting, 5 mCi (185 MBq) of 18F-FP-CIT was injected intrave-
nously, and the images were acquired in the three-dimensional mode at 120 KVp and 380 mAs
during a 20-minutes session, performed at 90 minutes after injection.
Quantitative analysis of 18F-FP-CIT PET data
Quantitative analyses were performed following a modified version of a previously described
procedure [22, 23]. Image processing was performed using SPM8 (Wellcome Department of
Imaging Neuroscience, Institute of Neurology, UCL, London, UK) with Matlab 2013a for Win-
dows (Math Works, Natick, MA, USA). Quantitative analyses were based on volumes of inter-
est (VOIs), which were defined based on a template in standard space. To remove inter-subject
anatomical variability, all reconstructed PET images were spatially normalized to the Montreal
Neurology Institute (MNI) template space using a standard 18F-FP-CIT PET template which
was generated using 18F-FP-CIT PET and T1 MR images from 13 normal controls. Eight VOIs
of bilateral striatal subregions and one occipital VOI were drawn on a co-registered spatially
normalized single T1 MR and 18F-FP-CIT PET template image on MRIcro version 1.37 (Chris
Rorden, Columbia, SC, USA), based on a previous study [22]. The striatum was divided into
the caudate, the ventral striatum, the anterior putamen, and the posterior putamen. The VOI
for the ventral striatum was defined according to previously defined criteria [24], and the
boundary between the anterior and the posterior putamen was the anterior commissure coro-
nal plane. The outer boundaries of the striatal subregions were visually determined by the char-
acteristic dense grey signal of the striatum, which readily distinguished these subregions from
adjacent structures. These VOIs were adjusted by a minor translation in our in-house editing
software called ANTIQUE [25]. DAT activity was calculated by the non-displaceable binding
potential (BPND), which was defined as (mean standardized uptake value of the striatal subre-
gions VOI–mean standardized uptake value of the occipital VOI)/mean standardized uptake
value of the occipital VOI [26].
Statistical analyses
The Mann-Whitney U test and chi-square test were used to compare demographic characteris-
tics between the PR and CR groups. The Mann-Whitney U test was also used to compare the
DAT activity of each striatal subregion between the groups. Statistical analyses and plotting
were performed using IBM SPSS Statistics 21 (IBM, Armonk, NY, USA), and p< 0.05 was con-
sidered statistically significant.
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Results
Study subjects and demographic data
A total of 52 DIP patients who showed a visually normal DAT density on 18F-FP-CIT PET
were selected from historical medical record. However, two patients who had a DAT density
slightly below the cut-off were excluded. Among the remaining 50 patients, nine had recovered
partially (PR group) from parkinsonism, and the other 41 had recovered completely (CR
group).
The demographic characteristics of the subjects are shown in Table 2, and the original
data are presented in S1 File. There was no significant difference in sex distribution or age
at the time of the PET scan between the groups. The PR and CR groups were similar in age
at onset of parkinsonian symptoms, the time from onset of parkinsonism to PET scan, and
UPDRS motor scores. The composition of the offending drugs was also comparable.
The clinical information of the PR patients is presented in Table 3. Parkinsonism occurred
between the ages of 53 and 83 years in five men and four women. The patients visited the hos-
pital 1 to 26 months after symptom onset and were followed up for 12 to 60 months after cessa-
tion of the offending drugs. The UPDRS motor scores varied between 19 and 56 points at
initial examination but improved to 6–10 points at follow-up.
DAT density on 18F-FP-CIT PET
The 18F-FP-CIT uptake in the striatal subregions in the two groups are shown in Table 4. S1
File, and Fig 1. The PR patients showed a lower DAT density in the ventral striatum and puta-
men compared with the CR patients. In the putamen, there were significant differences in both
the anterior and posterior putamen. The DAT density of the caudate was comparable between
the PR and the CR patients.
Table 2. Demographic characteristics of the subjects.
PR (n = 9) CR (n = 41) P value
Male/female, n 5/4 10/31 0.106a
Age at PET scan, yr 70.7 (66.0–77.0) 71.5 (67.8–77.0) 1.000b
Age at onset of parkinsonism, yr 69.9 (64.9–75.9) 70.3 (66.7–75.5) 0.882b
Time from onset to PET scan, yr 1.0 (0.4–1.6) 0.4 (0.2–1.4) 0.921b
UPDRS motor score 27 (20–36) 27 (20–33) 0.637b
Offending drugs 0.878a
Antiemetic 5 (56%) 18 (44%)
Flunarizine 2 (22%) 7 (17%)
Diltiazem 0 (0%) 2 (5%)
Valproate 0 (0%) 2 (5%)
Antipsychotic 1 (11%) 2 (5%)
SSRI 0 (0%) 2 (5%)
Two or more 1 (11%) 8 (20%)
Data are expressed as median (interquartile range) or n (%).
PR: patients who recovered partially; CR: patients who recovered completely, PET: Positron emission tomography; UPDRS: Uniﬁed Parkinson’s disease
rating scale; N/A: not applicable.
a Chi-square test
b Mann-Whitney U test
doi:10.1371/journal.pone.0157410.t002
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Discussion
In the present study, the PR patients with DIP showed a relatively lower DAT density in puta-
men and ventral striatum compared with the CR patients, even though all patients of both
groups had normal DAT density.
Persistent parkinsonism in these patients seems to be surprising, but similar cases have
already been observed in previous studies. In the first study using PET in patients with DIP,
Burn and Brooks presented nine patients whose DAT imaging was normal [11]. Among them,
five did not recover completely after more than 6 months of drug washout. The major remnant
symptom was postural tremor, but two patients showed a rest tremor, and one showed brady-
kinesia. Olivares Romero et al. also presented two patients, among 15 with normal 123I-FP-CIT
SPECT images, who did not fully recover during the 14 or 15 months of follow-up [10]. How-
ever, almost none of the other studies assessed the recovery of parkinsonism in DIP patients
with normal DAT images. Other studies classified the partially recovered patients as PD [3]
and either excluded them from study [27] or did not follow-up until the completion of recovery
[6, 7, 9, 12].
The parkinsonian symptoms of partially recovered patients did not aggravate again during
follow-up period. Previous reports described that the parkinsonian symptoms of antedated PD
developed within 2.5 years after DIP remission [13–16]. While, for eight of nine patients of this
study who recovered partially from DIP showed stable parkinsonism for more than 2 years,
their clinical courses seem to be different from that of antedated or unmasked classical PD.
Table 3. Clinical information for partially recovered patients with drug-induced parkinsonism.








Initial symptoms Follow-up symptoms Follow-up
(mo)
Offending drug
UPDRS III RT PT R BK PI UPDRS III RT PT R BK PI
1 M 65 10 12 20 -/- ++/++ ++/++ +/+ + 10 -/- +/+ +/+ +/+ - 60 Amitriptyline,
mirtazapine
2 M 65 6 3 40 -/- ++/+++ ++/++ +++/+++ + 7 -/- +/- +/- +/- - 27 Flunarizine
3 M 70 4 9 32 -/+ +/++ ++/++ ++/++ - 7 -/- -/- -/+ -/+ - 26 Flunarizine
4 M 75 2 1 25 -/++ +/+ -/+ ++/++ - 9 -/- -/+ -/+ -/+ - 41 Levosulpiride
5 M 83 2 1 27 -/- -/- ++/+++ ++/+++ + 9 -/- -/- -/+ -/+ - 38 Levosulpiride
6 F 53 1 12 56 ++/+ +++/+++ +++/++ +++/+++ + 9 +/- +/- +/- +/- - 26 Metoclopramide
7 F 67 24 26 20 +/+ ++/+ +/+ ++/+ + 10 -/- +/+ +/+ +/+ - 57 Perphenazine
8 F 75 1 2 32 -/- +/+ -/+ +/++ +
+
10 -/- +/+ -/+ -/+ - 42 Levosulpiride
9 F 77 12 24 19 +/- +/+ +/- +/+ - 6 -/- +/- +/- +/- - 12 Levosulpiride
RT: rest tremor; PT: postural tremor; R: rigidity; BK: bradykinesia; PI: postural instability
doi:10.1371/journal.pone.0157410.t003
Table 4. The 18F-FP-CIT uptake in striatal subregions.
PR CR P value
Caudate 2.20 (1.74–2.61) 2.54 (2.18–3.11) 0.069
Ventral striatum 2.85 (2.19–3.39) 3.38 (2.92–3.76) 0.018
Putamen 2.85 (2.31–3.39) 3.39 (2.96–4.05) 0.016
Anterior 3.13 (2.46–3.74) 3.67 (3.19–4.39) 0.018
Posterior 2.67 (2.16–3.18) 3.21 (2.82–3.83) 0.017
Data are expressed as median (interquartile range).
PR: patients who recovered partially; CR: patients who recovered completely
doi:10.1371/journal.pone.0157410.t004
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Therefore, we can speculate that the parkinsonism was due to permanent dopaminergic dys-
function induced or unmasking very mild and stable PD pathology by offending drugs.
Absent parkinsonian symptom before administration of offending drugs and persistent parkin-
sonism after drug discontinuation imply permanent presynaptic dysfunction or the loss of presyn-
aptic dopaminergic neurons. The pharmacological dysfunction of the D2 receptor by the offending
drug is the widely accepted pathophysiology of DIP, whereas there are several studies suggesting a
neurotoxic effect of D2 receptor blocking agents on dopaminergic neurons. An experimental study
demonstrated that a pyridiniummetabolite derived from haloperidol (HPP+) had a neurotoxic
effect on dopaminergic and serotonergic neurons [28]. Another animal study showed that chronic
administration of haloperidol resulted in oxidative damage and decreased turnover of dopamine
and norepinephrine [29], and that tyrosine hydroxylase (TH) activity of the substantia nigra was
persistently down-regulated in rats treated for 8 weeks with haloperidol, despite a recovery in the
TH-positive cell count [30]. In a clinical study, elevated levels of oxidative markers were observed
in the CSF of patients with tardive dyskinesia [31]. Moreover, not only a reduced TH level but also
neurodegeneration was observed in the ventral pallidum of haloperidol- or eticlopride-treated rats
[32]. These results support that exposure to dopamine receptor blocking agents may cause bio-
chemical or pathological changes in the dopaminergic system of the human brain, even though
there is no direct evidence of neurodegeneration by offending drugs in patients with DIP.
Despite the clinical course of partially recovered patients, possible underlying pathology
cannot be ruled out. Two autopsy studies found neuronal loss of substantia nigra and Lewy
bodies in DIP patients whose parkinsonism disappeared completely. The researchers postu-
lated that mild PD pathology may underlie even pure DIP, and this suggestion accords with
our results. However, there is no pathological report on patients showing both persistent par-
kinsonism and normal range of DAT activity until now, hence further autopsy studies to exam-
ine underlying pathology are warranted.
Fig 1. The 18F-FP-CIT uptake in the striatal subregions of partially (PR) and completely recovered (CR) patients and healthy controls
(HC).
doi:10.1371/journal.pone.0157410.g001
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Semi-quantitative analysis revealed that the 18F-FP-CIT uptake in PR patients was reduced
to 86.0–89.4% of that in the CR patients. The motor symptoms of PD appear when there is 48–
68% nigral dopaminergic cell loss [33]; therefore, this reduction in the rate of 18F-FP-CIT
uptake in PR patients seems to be insufficient to develop clinical symptoms. However, previous
PET studies on parkinsonism patients with frontotemporal dementia (FTD) or Alzheimer's
disease (AD) demonstrated only a 20% reduction in ligand uptake compared with healthy con-
trols [34, 35]. Such a relatively low rate of reduction may imply concomitant damage of the
postsynaptic neurons in neurodegenerative disease presenting parkinsonism. A pathological
study found that the dopaminergic and dopaminoreceptive neurons were decreased equally in
patients with FTD and parkinsonism linked to chromosome 17 (FTDP-17) [36]; another path-
ological study showed that AD patients with parkinsonism had significant pre- and postsynap-
tic neuronal loss when compared with those without parkinsonism [37]. Similarly, in terms of
DIP, if the pharmacological blocking effect of the offending drug also becomes neurotoxic,
then relatively lower amount of presynaptic neuronal loss may be sufficient to present symp-
toms of parkinsonism. To confirm this hypothesis, further studies exploring postsynaptic activ-
ity in DIP patients having both normal DAT images and persistent parkinsonism are needed.
Several previous studies have demonstrated that the visual interpretation of DAT imaging is
useful to differentiate pure DIP from unmasked PD [3, 9–11]. Moreover, recent studies have
distinguished pure DIP from unmasked PD using cut-off values of 1–2.5 SD below the mean
derived from normal data [3, 12]. We also recruited DIP patients with normal appearing DAT
images and ruled out two DIP patients among them who showed a binding potential slightly
lower than 2 SD below the mean from normal data. This process may prevent inclusion of
patients with very early-stage PD among the study subjects.
The present study had some limitations. Although longitudinal data were used, its retro-
spective design was insufficient for drawing clear conclusions. Second, the duration of follow-
up of the subjects was relatively short for determining whether the parkinsonism of the PR
patients was progressive. Third, it is unclear whether there were permanent postsynaptic
changes or any relationship between the presynaptic and postsynaptic environment. Also, PET
data do not exactly reflect the neuronal status. Pathological studies are required to evaluate the
implications of the present results.
In conclusion, we report relatively lower DAT activity in patients who have not recovered
completely from DIP, despite normal appearing DAT images, compared with those who recov-
ered completely. This result suggests that persistent DIP in patients with visually normal DAT
imaging may be associated with subtle decrement of DAT activity.
Supporting Information
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